Physician profile
Ratnesh Kumar
NPI 1194750828
$8,546.90
in general payments reported to CMS, 2019-2025
56 companies · $2,347 in 2025
The $2,347 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $12.69 · 2021: $30.92 · 2022: $1,403 · 2023: $2,185 · 2024: $2,434 · 2025: $2,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,966.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,028.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $852.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $766.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $654.09 | 2022-2025 | |
| Novo Nordisk INC | $588.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $320.21 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.54 | 2021-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Abbott Laboratories | $245.93 | 2022-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $184.03 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.64 | 2019-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $157.59 | 2024-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $153.02 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Shield Therapeutics INC | $145.60 | 2024-2025 | |
| Ardelyx, INC. | $128.59 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $125.93 | 2022-2024 | Trintellix |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratnesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.